Literature DB >> 25680385

PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake.

Christoph Rischpler1, Nicolas Langwieser2, Michael Souvatzoglou3, Anja Batrice2, Sandra van Marwick3, Julian Snajberk2, Tareq Ibrahim2, Karl-Ludwig Laugwitz4, Stephan G Nekolla5, Markus Schwaiger5.   

Abstract

AIMS: F-18 fluorodeoxyglucose (FDG) myocardial PET imaging is since more than two decades considered to delineate glucose utilization in dysfunctional but viable cardiomyocytes. Late gadolinium enhancement (LGE) MRI was introduced more than a decade ago and identifies increased extravascular space in areas of infarction and scar. Although the physiological foundation differs, both approaches are valuable in the prediction of functional outcome of the left ventricle, but synergistic effects are yet unknown. We aimed to compare the improvement of LV function after 6 months based on the regional FDG uptake and the transmurality of scar by LGE in patients early after acute myocardial infarction (AMI). METHODS AND
RESULTS: Twenty-eight patients with primary AMI underwent simultaneous PET/MRI for assessment of regional FDG uptake and degree of LGE transmurality 5-7 days after PCI. Follow-up by MRI was performed in 20 patients 6 months later. Myocardium was defined 'PET viable' based on the established threshold of ≥ 50% FDG uptake compared with remote myocardium or as 'MRI viable' when LGE transmurality of ≤ 50% was present. Regional wall motion was measured by MRI. Ninety-five dysfunctional segments were further analysed regarding regional wall motion recovery. There was a substantial intermethod agreement for segmental LGE transmurality and reduction of FDG uptake (κ = 0.65). 'PET viable' and 'MRI viable' segments showed a lower wall motion abnormality score (PET: initial: 1.4 ± 0.6 vs. 1.9 ± 0.8, P < 0.008; follow-up: 0.5 ± 0.7 vs. 1.5 ± 1.0, P < 0.0001; MRI: initial: 1.5 ± 0.6 vs. 2.0 ± 0.8, P < 0.002; follow-up: 0.7 ± 0.8 vs. 1.6 ± 1.0, P < 0.0001) and a better regional wall motion improvement (PET: -0.9 ± 0.7 vs. -0.4 ± 0.7, P < 0.0007; MRI: -0.8 ± 0.7 vs. -0.4 ± 0.7, P < 0.009) compared with 'PET non-viable' or 'MRI non-viable' segments, respectively. Eighteen per cent of the dysfunctional segments showed discrepant findings ('PET non-viable' but 'MRI viable'). At follow-up, the regional wall motion of these segments was inferior compared with 'PET viable/MRI viable' segments (1.1 ± 0.8 vs. 0.5 ± 0.7, P < 0.01), had an inferior functional recovery (-0.5 ± 0.6 vs. -0.9 ± 0.7, P < 0.03), but showed no difference compared with concordant 'PET non-viable/MRI non-viable' segments.
CONCLUSION: The simultaneous assessment of LGE and FDG uptake using a hybrid PET/MRI system is feasible. The established PET and MRI 'viability' parameter prior to revascularization therapy also predicts accurately the regional outcome of wall motion after AMI. In a small proportion of segments with discrepant FDG PET and LGE MRI findings, FDG uptake was a better predictor for functional recovery. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2015. For permissions please email: Journals.permissions@oup.com.

Entities:  

Keywords:  FDG; Late gadolinium enhancement; Myocardial infarction; PET/MRI; Viability; Wall motion recovery

Mesh:

Substances:

Year:  2015        PMID: 25680385     DOI: 10.1093/ehjci/jeu317

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  36 in total

1.  Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study.

Authors:  Roni Nielsen; Anders Jorsal; Peter Iversen; Lars Poulsen Tolbod; Kirsten Bouchelouche; Jens Sørensen; Hendrik Johannes Harms; Allan Flyvbjerg; Lise Tarnow; Caroline Kistorp; Ida Gustafsson; Hans Erik Bøtker; Henrik Wiggers
Journal:  J Nucl Cardiol       Date:  2017-08-02       Impact factor: 5.952

Review 2.  Cardiovascular PET/MR: We need evidence, not hype.

Authors:  Afshin Farzaneh-Far; Raymond Y Kwong
Journal:  J Nucl Cardiol       Date:  2016-11-29       Impact factor: 5.952

Review 3.  Myocardial Viability and Revascularization: Current Understanding and Future Directions.

Authors:  Pavan Patel; Alexander Ivanov; Kumudha Ramasubbu
Journal:  Curr Atheroscler Rep       Date:  2016-06       Impact factor: 5.113

Review 4.  Advances in PET/MR instrumentation and image reconstruction.

Authors:  Jorge Cabello; Sibylle I Ziegler
Journal:  Br J Radiol       Date:  2016-07-22       Impact factor: 3.039

5.  Cardiac PET/MRI enters the clinical arena! Finally….

Authors:  C Rischpler; N Langwieser; S G Nekolla
Journal:  J Nucl Cardiol       Date:  2016-09-23       Impact factor: 5.952

6.  Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism.

Authors:  Roni Nielsen; Anders Jorsal; Peter Iversen; Lars Tolbod; Kirsten Bouchelouche; Jens Sørensen; Hendrik Johannes Harms; Allan Flyvbjerg; Hans Erik Bøtker; Henrik Wiggers
Journal:  J Nucl Cardiol       Date:  2016-07-29       Impact factor: 5.952

Review 7.  Applications of PET-MR Imaging in Cardiovascular Disorders.

Authors:  Rhanderson Cardoso; Thorsten M Leucker
Journal:  PET Clin       Date:  2020-07-21

8.  Technical aspects of cardiac PET/MRI.

Authors:  Atsuro Masuda; Ayaka Nemoto; Yasuchika Takeishi
Journal:  J Nucl Cardiol       Date:  2018-02-21       Impact factor: 5.952

Review 9.  Positron emission tomography/MRI for cardiac diseases assessment.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Nagara Tamaki
Journal:  Br J Radiol       Date:  2020-02-14       Impact factor: 3.039

Review 10.  Clinical imaging of cardiovascular inflammation.

Authors:  Claudia Calcagno; Zahi A Fayad
Journal:  Q J Nucl Med Mol Imaging       Date:  2020-02-18       Impact factor: 2.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.